Palla Pharma logo

PAL - Palla Pharma Share Price

A$0.585 0.0  0.0%

Last Trade - 4:38am

Sector
Healthcare
Size
Small Cap
Market Cap £50.2m
Enterprise Value £60.2m
Revenue £12.3m
Position in Universe 865th / 1842
Bullish
Bearish
Unlock PAL Revenue
Momentum
Relative Strength (%)
1m -0.39%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -43.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
3.68 10.6 22.3 46.6 54.8 22.1 63.0 72.0 +43.1%
+133.3
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, PallaPharma Ltd revenues decreased 60% to A$22.1M. Net lossincreased from A$7.6M to A$34.8M. Revenues reflect adecrease in demand for the Company's products and servicesdue to unfavorable market conditions. Higher net lossreflects Occupancy expenses increase of 42% to A$2.3M(expense), Net exchange losses on foreign currency increasefrom A$311K to A$668K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

PAL Revenue Unlock PAL Revenue

Net Income

PAL Net Income Unlock PAL Revenue

Normalised EPS

PAL Normalised EPS Unlock PAL Revenue

PE Ratio Range

PAL PE Ratio Range Unlock PAL Revenue

Dividend Yield Range

PAL Dividend Yield Range Unlock PAL Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
PAL EPS Forecasts Unlock PAL Revenue
Profile Summary

Palla Pharma Limited, formerly TPI Enterprises Limited, is an Australia-based company, which is engaged in the manufacture and supply of alkaloids to international markets. The Company's segment is supplying narcotic raw materials (NRM), including morphine and thebaine to the active pharmaceutical ingredient sector. The Company uses its technology for solvent free extraction of alkaloids from opium poppies. It sources its raw materials from Australian poppy growers in Tasmania and Victoria. The Company assists customers with NRM conversions, such as methylation and oxidiation reactions. The Company sells and exports culinary poppy seed throughout Australia and around the world. The Company focuses on manufacture and supply of the products, including concentrate of poppy straw (oripavine), concentrate of poppy straw (thebaine), concentrate of poppy straw (morphine), concentrate of poppy straw (codeine), technical oripavine, technical codeine, noscapine and certified alkaloid impurities.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated February 5, 2004
Public Since August 13, 2015
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 153,947,977
Free Float (0.0%)
Eligible for
ISAs
SIPPs
PAL Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for PAL
Upcoming Events for PAL
Frequently Asked Questions for Palla Pharma
What is the Palla Pharma share price?

As of 4:38am, shares in Palla Pharma are trading at A$0.585, giving the company a market capitalisation of £50.2m. This share price information is delayed by 15 minutes.

How has the Palla Pharma share price performed this year?

Shares in Palla Pharma are currently trading at A$0.585 and the price has moved by -24.05% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Palla Pharma price has moved by -30.58% over the past year.

What are the analyst and broker recommendations for Palla Pharma?

Of the analysts with advisory recommendations for Palla Pharma, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Palla Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Palla Pharma next release its financial results?

Palla Pharma is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Palla Pharma dividend yield?

Palla Pharma does not currently pay a dividend.

Does Palla Pharma pay a dividend?

Palla Pharma does not currently pay a dividend.

When does Palla Pharma next pay dividends?

Palla Pharma does not currently pay a dividend.

How do I buy Palla Pharma shares?

To buy shares in Palla Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Palla Pharma?

Shares in Palla Pharma are currently trading at A$0.585, giving the company a market capitalisation of £50.2m.

Where are Palla Pharma shares listed? Where are Palla Pharma shares listed?

Here are the trading details for Palla Pharma:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: PAL
What kind of share is Palla Pharma?

Based on an overall assessment of its quality, value and momentum, Palla Pharma is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Palla Pharma share price forecast 2021?

Shares in Palla Pharma are currently priced at A$0.585. At that level they are trading at 80.34% discount to the analyst consensus target price of 0.00.

Analysts covering Palla Pharma currently have a consensus Earnings Per Share (EPS) forecast of 0.03 for the next financial year.

How can I tell whether the Palla Pharma share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Palla Pharma. Over the past six months, the relative strength of its shares against the market has been -26.21%. At the current price of A$0.585, shares in Palla Pharma are trading at -19% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Palla Pharma PE Ratio?

We were not able to find PE ratio data for Palla Pharma.

Who are the key directors of Palla Pharma?

Palla Pharma's management team is headed by:

Ross Dobinson - CHM
Simon Moore - NID
Stuart Black - NID
Brendan Middleton - CEO
Sue MacLeman - NED
Mark Licciardo - SEC
Iain Ross - NED
Who are the major shareholders of Palla Pharma?

Here are the top five shareholders of Palla Pharma based on the size of their shareholding:

Washington H Soul Pattinson and Company Ltd Investment Advisor
Percentage owned: 16.27% (25.0m shares)
Thorney Opportunities Ltd Corporation
Percentage owned: 9.45% (14.6m shares)
Wentworth Williamson Management Pty Limited Investment Advisor
Percentage owned: 6.93% (10.7m shares)
TIGA Trading Pty Ltd Investment Advisor
Percentage owned: 5.8% (8.94m shares)
Australian Ethical Investment Ltd. Investment Advisor
Percentage owned: 5.19% (7.99m shares)
Similar to PAL
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.